AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27213613
Drug: Lancet weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lancet weight of 25 g
Trial: 27213613
Drug: Lancet weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lancet weight of 85 g
Trial: 27213613
Drug: Lancet weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lancet weight of 135 g
Trial: 27213613
Drug: Lancet weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lancet weight of 265 g
Trial: 27213613
Drug: Histamine 1
RxNorm normalized name: Antihistamine 12 Hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine 1 mg/mL (positive control)
Trial: 27213613
Drug: Histamine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine 10 mg/mL (positive control)
Trial: 19202157
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily (n = 118)
Trial: 17005362
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg of etomidate (priming group)
Trial: 15316868
Drug: Etidronate 200
RxNorm normalized name: etidronate 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 200 mg/day (intermittent treatment)
Trial: 11736716
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (6 mg twice daily, increasing to 9 mg twice daily after 6 weeks)
Trial: 9522321
Drug: HRT (hormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (hormonal replacement therapy) as oral or transdermal oestradiol supplemented with progestogen
Trial: 9522321
Drug: Oral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sequential oestrogen plus progestogen
Trial: 3047394
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (1.5 mg/2.5 cm2)
Trial: 29254669
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1.5 mg/kg)
Trial: 25027194
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (0.1 mg/kg)
Trial: 21698591
Drug: Intra-articular infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular infiltration of 10 ml of 0.25% bupivacaine
Trial: 21698591
Drug: Portal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal infiltration of 10 ml of 0.25% bupivacaine
Trial: 52001
Drug: Urokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase and Glucose infusion
Trial: 29246820
Drug: Standard-dose filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose filgrastim (10 µg/kg BW per day)
Trial: 29246820
Drug: Reduced-dose filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose filgrastim (5 µg/kg BW per day)
Trial: 23172749
Drug: Etanercept (ETA)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETA) treatment for 1 year
Trial: 16926353
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (333 U/kg initial dose, followed by 250 U/kg every 12 hours)
Trial: 16926353
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (100 IU/kg every 12 hours)
Trial: 12953129
Drug: G‐CSF mobilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF mobilized PB and BM
Trial: 12953129
Drug: G‐CSF and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF and GM‐CSF mobilized grafts
Trial: 12953129
Drug: G‐CSF stimulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF stimulated PB
Trial: 10899449
Drug: Catalyzed Signal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catalyzed Signal Amplification system with DYS1 and DYS2 antibodies
Trial: 10899449
Drug: Control patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients with DYS1 and DYS2 antibodies
Trial: 6609933
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 0.5 mg/kg/day for 7 days
Trial: 6609933
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 1.0 mg/kg (single injection)
Trial: 30098822
Drug: Combined Manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Manual Therapy (MT) and Diadynamic (DD) currents (MTDD)
Trial: 30098822
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy (MT) alone
Trial: 16968874
Drug: Epirubicin (E)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (E) 110 mg/m2 followed by paclitaxel (P) 250 mg/m2 followed by intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2)
Trial: 15882216
Drug: Transmucosal anaesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmucosal anaesthetic patches containing lidocaine (46.1 mg/2 cm(2))
Trial: 9391998
Drug: Ipriflavone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (600 mg/day) plus calcium (500 mg/day)
Trial: 9391998
Drug: Ipriflavone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (400 mg/day) plus conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Trial: 9391998
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Trial: 3308571
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of cefoxitin (2 g)
Trial: 3308571
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of cefoxitin (2 g, 1 g, and 1 g)
Trial: 26427705
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg qid on day 0 and bid on days 1 to 7
Trial: 26427705
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg bid for 7 days
Trial: 26427705
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg qid for 7 days
Trial: 26427705
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg bid in IMs
Trial: 26427705
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg bid in PMs
Trial: 24174910
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block using 1 mL·kg(‐1) lidocaine (1%) after 2 mg·kg(‐1) ketamine IV
Trial: 24174910
Drug: 2 mg·kg(‐1) ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg·kg(‐1) ketamine IV only
Trial: 16555144
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment controls
Trial: 27744007
Drug: NO3−-rich beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3−-rich beetroot juice (140 mL day−1; 8.4 mmol NO3− day−1)
Trial: 20884893
Drug: Control (delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (delayed evaluation or treatment for 6 months)
Trial: 18186976
Drug: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) administered with a 12-h or 24-h interval between tablets.
Trial: 16338010
Drug: OxLDL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxLDL levels >76 U/L
Trial: 16338010
Drug: OxLDL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxLDL levels >76 U/L in TnT negative group
Trial: 16338010
Drug: OxLDL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxLDL levels ≤76 U/L
Trial: 8616946
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg orally twice daily for 14 days)
Trial: 1917227
Drug: Nandrolone-decanoate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nandrolone-decanoate (100 mg weekly i.m. injection)
Trial: 7050440
Drug: Special Intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special Intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels
Trial: 3873785
Drug: Bypass surgery
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bypass surgery (beta blockers)
Trial: 27516093
Drug: Utidelone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone (25 to 35 mg/m2/day intravenously infused once daily for 5 days) in combination with capecitabine (2000 mg/m2 divided in two equal daily oral doses for 14 days)
Trial: 27516093
Drug: Utidelone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone (40 mg/m2/day intravenously infused once daily for 5 days) as monotherapy
Trial: 6270998
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber diet (59 g neutral detergent fiber)
Trial: 6270998
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (21 g neutral detergent fiber)
Trial: 6270998
Drug: Low fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fiber diet (21 g neutral detergent fiber)
Trial: 18160763
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB) - 50 mg of losartan potassium administered once daily for one year
Trial: 15886228
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (6 mg)
Trial: 10785238
Drug: 100 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Trial: 10785238
Drug: 150 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Trial: 11922560
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg once daily
Trial: 9301500
Drug: Budesonide 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 4.5 mg twice daily
Trial: 9301500
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg once daily
Trial: 8280824
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg q.d.s., 7 days)
Trial: 8280824
Drug: Liquid Gaviscon
RxNorm normalized name: Gaviscon Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid Gaviscon (sodium alginate compound)
Trial: 3552444
Drug: Cryoprecipitate infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate infusion
Trial: 23449130
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a mixture of Trifolium pratense flower extract and a biomimetic peptide
Trial: 21593619
Drug: Twice-weekly peginterferon-α-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-weekly peginterferon-α-2a 180 μg/week (for 4 weeks, followed by weekly dosing) and weight-based ribavirin (1-1.2 g/day)
Trial: 21593619
Drug: Weekly peginterferon-α-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly peginterferon-α-2a 180 μg/week and weight-based ribavirin (1-1.2 g/day)
Trial: 19619692
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (UFH) bolus 70 IU/kg
Trial: 19619692
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin (1 mg/kg every 12 hours for 2.5 days)
Trial: 11044536
Drug: Prostaglandin E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E(2) intravaginal gel (2 mg)
Trial: 11044536
Drug: Prostaglandin E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E(2) intracervical gel (0.5 mg)
Trial: 3525584
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (NTC)
Trial: 27914492
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (90 mg twice daily) plus low-dose aspirin (81-100 mg daily) for 3 months, then ticagrelor plus placebo for 12 months
Trial: 27914492
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus low-dose aspirin (81-100 mg daily) for 3 months, then continuation of ticagrelor plus aspirin
Trial: 25618415
Drug: GEMOXEL (GEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOXEL (GEM 1,000 mg/m², L-OHP 100 mg/m², CAP 1,500 mg/m²/day)
Trial: 25618415
Drug: GEM (GEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM (GEM 1,000 mg/m²)
Trial: 24524600
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (n = 70)
Trial: 21943132
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal therapy involving removal of subgingival and supragingival calculus and plaque biofilm by scaling and root‐planing.
Trial: 16530290
Drug: IFN-alpha treatment
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha treatment in CHB patients
Trial: 16530290
Drug: IFN-alpha treatment
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha treatment in CHC patients
Trial: 10613766
Drug: Purple grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple grape juice (5-7.5 mL/(kg. d) for 7-10 days)
Trial: 10613766
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (5-7.5 mL/(kg. d) for 7-10 days)
Trial: 10613766
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (5-7.5 mL/(kg. d) for 7-10 days)
Trial: 2923769
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.25% bupivacaine through an extradural catheter
Trial: 2923769
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.25% bupivacaine through a paravertebral catheter
Trial: 29079990
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (2 × 10^9 CFU/g each of Lactobacillus acidophilus strain T16, Lactobacillus casei strain T2, and Bifidobacterium bifidum strain T1 plus 800 mg inulin)
Trial: 29103871
Drug: Olaparib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (100 mg twice daily) plus paclitaxel (80 mg/m2 intravenously)
Trial: 29103871
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus paclitaxel (80 mg/m2 intravenously)
Trial: 17541058
Drug: Cortisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone (25 mg)
Trial: 17541058
Drug: Cortisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone (25 mg) + Propranolol (40 mg)
Trial: 2205962
Drug: Early occupational
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early occupational therapy (1-3 days after injury)
Trial: 6107722
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of acetylsalicylic acid
Trial: 18482867
Drug: Valerian (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian (300 mg nightly for 2 weeks)
Trial: 11332873
Drug: Amoxicilina 250
RxNorm normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicilina 250 mg/5 ml oral suspension
Trial: 11332873
Drug: Amoxicilina 500
RxNorm normalized name: Amoxicilina
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicilina 500 mg capsule
Trial: 11332873
Drug: Amoxil 250
RxNorm normalized name: Amoxil 250mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxil 250 mg/5 ml oral suspension
Trial: 11332873
Drug: Amoxil capsule
RxNorm normalized name: Amoxi Drop
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxil capsule 500 mg
Trial: 2685676
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous oxytocin infusion
Trial: 2685676
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous oxytocin infusion (every 8 minutes)
Trial: 3404378
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous oxytocin infusion
Trial: 23545926
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid with lidocaine (HA+L)
Trial: 23545926
Drug: Both HA
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HA and HA+L
Trial: 8764799
Drug: 50 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/ml latanoprost once daily
Trial: 8764799
Drug: 15 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 micrograms/ml latanoprost twice daily
Trial: 30796036
Drug: Trastuzumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab treatment (after exclusion of lowest HER2 expressers)
Trial: 26435365
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart
Trial: 27009108
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30
Trial: 25007693
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 100 microgram/kg before skin incision
Trial: 25007693
Drug: Ilioinguinal/iliohypogastric nerve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal/iliohypogastric nerve block with 0.25 ml/kg bupivacaine 0.5% before skin incision
Trial: 23158942
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine for promoting blood circulation and removing blood stasis
Trial: 19283561
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose naltrexone (VLNTX) 0.125 or 0.250 mg per day
Trial: 19283561
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose naltrexone (VLNTX)
Trial: 17224720
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg/d initiated, titrated to a maximum of 16 mg/d)
Trial: 2723116
Drug: HP 029
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP 029 (5 to 200 mg)
Trial: 27322814
Drug: Bosentan (ET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (ET receptor antagonist)